GENZ-644470: Phase II/III started

Genzyme disclosed that in March it began the double-blind, U.S. Phase II/III LEAP trial to compare 3 dosages of GENZ-644470 vs. 3 dosages of Renvela sevelamer or placebo in 315 patients. Genzyme marke...